A Natural History Study to Evaluate Functional and Anatomical Progression in Retinitis Pigmentosa

Overview

This study will assess the progression of RP as seen on newer modalities including spectral-domain optical coherence (SD-OCT) and macular assessment integrity (MAIA) microperimetry to evaluate disease status. Understanding the natural history of the disease is not only essential to monitoring and comparing patient populations in clinical trials. It is also fundamental in the predevelopment phase in order to optimize the study duration needed to observe a statistically significant outcome. Furthermore, since the progression of RP is usually slow, relying on traditional tests can take an unfeasible length of time to observe any meaningful changes and assess therapeutic efficacy for new drugs. Therefore, the results of this study will be beneficial in establishing reliable endpoints and outcome measures for future clinical trials. Such outcome measures may be able to detect treatment response with more precision. More importantly, investigators may be able to detect changes early enough to prevent irreversible vision loss.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: March 2024

Arms, Groups and Cohorts

  • Retinitis Pigmentosa
    • Patients with Retinitis Pigmentosa

Clinical Trial Outcome Measures

Primary Measures

  • Change in mean macular sensitivity (dB) over time as assessed by microperimetry
    • Time Frame: Baseline, every six months up to 2 years
    • Microperimetry (MAIA) will be used to test whether there is a change in sensitivity (dB) in the macula

Secondary Measures

  • Change in Best Corrected Visual Acuity (BVCA)
    • Time Frame: Baseline, every six months up to 2 years
    • Scoring will be determined by the number of letters gained or lost per month using Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score and visual acuity score together with an overall score range of 0 to 20/20 where 0 is the worst vision and 20/20 is the best.
  • Change in Ellipsoid Zone (EZ) width
    • Time Frame: Baseline, every six months up to 2 years
    • This will be assessed by spectral domain optical coherence tomography (SD-OCT)
  • Change in Quality of Life survey metrics
    • Time Frame: Baseline, every year up to 2 years
    • Scoring will be determined by the National Eye Institute’s Visual Function Questionnaire (NEI-VFQ-25). It has 25 question elements each with score ranging from 1(excellent) to 6(very poor), therefore a total minimum score of 25 and maximum score 150.
  • Change in mean retinal sensitivity
    • Time Frame: Baseline and at 2 years
    • Static Octopus Perimetry will be used to test whether there is a change in mean retinal sensitivity over time using its 30-2 program with III target
  • Correlation between change in visual functional and anatomical measures
    • Time Frame: Baseline, every six months up to 2 years
    • Change in visual function parameters such as Best Corrected Visual acuity (measured using ETDRS and visual acuity scale), mean macular sensitivity (quantified using MAIA microperimetry), mean retinal sensitivity (quantified using static Octopus perimetry) will be correlated to anatomical parameters such as Ellipsoid width (measurement on Optical Coherence Tomography)
  • Correlation between change in visual functional measures and Quality of Life survey metrics
    • Time Frame: Baseline, every year up to 2 years
    • Change in Quality of Life survey metrics (Scored using National Eye Institute’s Visual Function Questionnaire, NEI-VFQ-25) will be compared to visual function parameters such as Best Corrected Visual acuity (measured using ETDRS and visual acuity scale), mean macular sensitivity (quantified using MAIA microperimetry), mean retinal sensitivity (quantified using static Octopus perimetry)

Participating in This Clinical Trial

Inclusion Criteria

  • Age 18 years or older – Patients diagnosed with Retinitis Pigmentosa – Ability to provide informed consent – Ability to authorize use and disclosure of protected health information Exclusion Criteria:

  • Concomitant ocular pathology that limits central macular function, including but not limited to age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion – If EZ width ≤200µm

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Johns Hopkins University
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Peter A Campochiaro, M.D., Principal Investigator, Johns Hopkins University
  • Overall Contact(s)
    • Gulnar Hafiz, M.D., M.P.H., 4105020768, ghafiz@jhmi.edu

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.